Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells

Chun-Yu Liu(National Yang Ming Chiao Tung University), Ling‐Ming Tseng(National Yang Ming Chiao Tung University)

PLoS ONE

December 20, 2017

10.1371/journal.pone.0189007

Cited by 64

Related Papers

Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.

|Journal of Clinical Oncology|2024|75